Literature DB >> 25544182

Genetic variation in the promoter region of pro-inflammatory cytokine TNF-α in perinatal HIV transmission from Mumbai, India.

Swati Ahir1, Jayanti Mania-Pramanik2, Vijay Chavan1, Shilpa Kerkar1, Padmaja Samant-Mavani3, Ruchi Nanavati4, Preeti Mehta5.   

Abstract

Various host factors such as cytokines and HLA, regulate the immune system and influence HIV transmission to infants exposed to HIV-1 through their mothers. Tumor Necrosis Factor Alpha (TNF-α) is a strong pro-inflammatory mediator and thought to influence vulnerability to HIV infection (and/or) transmission. Polymorphisms in regulatory regions are known to govern the production of this cytokine. However, the association of these variations in perinatal HIV transmission is yet to be established. Present study aimed to evaluate if polymorphisms in promoter region of TNF-α gene is associated with perinatal HIV transmission. With informed consent from parents, infants' blood was collected for HIV screening and SNPs analysis at 2 loci: TNF (rs1800629) and TNF (rs361525) using PCR-SSP method. HIV positive (n = 27) and negative (n = 54) children at the end of 18th month follow up were considered for this study. GG genotype, responsible for low expression of TNF (rs1800629) was significantly (p = 0.005) higher in uninfected children, while higher GA genotype frequency was observed in infected children. The 'G' allele frequency was significantly higher in negative children (p = 0.016). We conclude that genotypic variants of TNF (rs1800629) are a likely contributor to perinatal HIV transmission. This provides new insights in markers of differential susceptibility to perinatal HIV transmission.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Genetic variants; Perinatal HIV; SNPs; TNF-α

Mesh:

Substances:

Year:  2014        PMID: 25544182     DOI: 10.1016/j.cyto.2014.11.022

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  2 in total

Review 1.  Host factors and early treatments to restrict paediatric HIV infection and early disease progression.

Authors:  Ketty Gianesin; Raffaella Petrara; Riccardo Freguja; Marisa Zanchetta; Carlo Giaquinto; Anita De Rossi
Journal:  J Virus Erad       Date:  2015-07-01

2.  CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins.

Authors:  Tengyi Zheng; Pei Chen; Yifan Huang; Jiayin Qiu; Chenliang Zhou; Ziyao Wu; Lin Li
Journal:  Front Cell Infect Microbiol       Date:  2021-07-19       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.